First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...
The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment after results ...
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...
Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...
1d
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
Stock drops after development setbackAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company announced it will discontinue development of tebapivat for sickle cell ...
Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.
Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the ...
A study of the long-term health impact of the Lahaina wildfires is inspiring a new model for disaster recovery and support.
Haisco Pharmaceutical Group has achieved a major regulatory milestone with the approval of China’s first small-molecule drug ...
Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results